Skip to main content
. 2020 Jul 11;75(7):1564–1581. doi: 10.1111/all.14364

Figure 4.

Figure 4

Ideal immune response to SARS‐CoV‐2 infection or a vaccine. Acute infection and the vaccine are expected to develop same type of an immune response with T‐ and B‐cell immunity and development of virus‐specific neutralizing antibodies. The normal immune response is characterized with one‐week typical viral respiratory disease without the development of asymptomatic virus carriers. This type of immune response is observed in almost all mild cases